Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes
In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of NAION and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.
Authors
- Nora D. Volkow (ORCID: https://orcid.org/0000-0001-6668-0908)
- Lindsey Wang
- Rong Xu (ORCID: https://orcid.org/0000-0003-3127-4795)
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
Institutions
- MetroHealth (US)
- National Institute on Alcohol Abuse and Alcoholism (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.26327
- Citations
- 17
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 29.02
Funders
- National Center for Advancing Translational Sciences